

Dr. Kimryn Rathmell is the Chair of Medicine and Physician-in-Chief at Vanderbilt University Medical Center. She is a physician-scientist studying the molecular biology of renal cell carcinomas and rare tumors of the kidney. She earned her MD and PhD in Biophysics at Stanford University. She completed internal medicine training at the University of Chicago and the University of Pennsylvania, and fellowship in medical oncology at the University of Pennsylvania. She joined Vanderbilt in 2015 to lead the Division of Hematology and Oncology.

Her research program focuses on understanding the molecular pathogenesis of renal cell carcinomas and spans early models of renal tumorigenesis, novel imaging strategies for diagnosis and screening of kidney cancer, epigenetic regulation of kidney cancers, metabolic features of tumorigenesis, and novel therapeutic strategies to overcome resistance to anti-angiogenic therapy and checkpoint targeted immunotherapy. With these bench to bedside strategies, her laboratory endeavors to integrate knowledge of pathways that promote cancer development with translational clinical studies, and uses these discoveries to develop robust approaches to improve the survival of patients with kidney cancers. She serves as the Deputy Director for Research Integration and Career Development for the Vanderbilt-Ingram Cancer Center and on the Board of Scientific Advisors for the National Cancer Institute.